Enanta Pharmaceuticals is a clinical stage biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and immunological diseases. Enanta’s research and development efforts include programs in the following disease areas: respiratory syncytial virus (RSV), SARS-CoV-2 (C0VID-19) and hepatitis B Virus (HBV) and chronic spontaneous urticaria (CSU).
Volume:
Minimum 15 minutes delayed. Source: LSEG
Recent Press Releases
December 9, 2024
Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)
December 6, 2024
Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV)
Upcoming Events
More events are coming soon.
- Print Page Print Page
- Email Alerts Email Alerts
- RSS Feeds RSS Feeds
- Contact IR Contact IR